netFormulary NHS
NHS Bath and North East Somerset, Swindon and Wiltshire CCG
Royal United Hospitals Bath NHS Foundation Trust
Great Western Hospitals NHS Foundation Trust
Salisbury NHS Foundation Trust
 Search
 Formulary Chapter 2: Cardiovascular system - Full Section
Notes:

Cardiology-related Prescribing Guidance

Please see our Prescribing Guidelines page for all prescribing guidance relating to this chapter.

Cardiology-related Shared Care Agreements

Please see our Shared Care Agreements page for all shared care agreements (SCAs) relating to this chapter.

 

Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
02.01 Positive inotropic drugs (0,0)
02.01.01 Cardiac glycosides (2,0)
Digoxin-specific antibody (1,2)
02.01.02 Phosphodiesterase type-3 inhibitors (2,0)
02.02 Diuretics (0,0)
02.02.01 Thiazides and related diuretics (3,5)
02.02.02 Loop diuretics (3,1)
02.02.03 Potassium-sparing diuretics and aldosterone antagonists (1,1)
Aldosterone antagonists (2,0)
02.02.04 Potassium-sparing diuretics with other diuretics (2,8)
02.02.05 Osmotic diuretics (1,0)
02.02.06 Mercurial diuretics (0,0)
02.02.07 Carbonic anhydrase inhibitors (0,0)
02.02.08 Diuretics with potassium (0,5)
02.03 Anti-arrhythmic drugs (0,0)
02.03.01 Management of arrhythmias (0,0)
02.03.02 Drugs for arrhythmias (0,1)
Supraventricular arrhythmias (3,0)
Supraventricular and ventricular arrhythmias (7,2)
Ventricular arrhythmias (1,0)
02.04 Beta-adrenoceptor blocking drugs (10,24)
02.05 Drugs affecting the renin-angiotensin system and some other antihypertensive drugs (0,0)
02.05.01 Vasodilator antihypertensive drugs (5,14)
02.05.02 Centrally acting antihypertensive drugs (2,1)
02.05.03 Adrenergic neurone blocking drugs (0,1)
02.05.04 Alpha-adrenoceptor blocking drugs (1,6)
Phaeochromocytoma (2,0)
02.05.05 Drugs affecting the renin-angiotensin system (0,1)
02.05.05.01 Angiotensin-converting enzyme inhibitors (ACE inhibitors) (3,23)
02.05.05.02 Angiotensin-II receptor antagonists (3,7)
02.05.05.03 Renin inhibitors (0,2)
02.06 Nitrates, calcium-channel blockers, and potassium-channel activators (0,0)
02.06.01 Nitrates (5,0)
02.06.02 Calcium-channel blockers (8,20)
02.06.03 Other anitanginal drugs (4,0)
02.06.04 Peripheral vasodilators and related drugs (1,4)
02.07 Sympathomimetics (0,0)
02.07.01 Inotropic sympathomimetics (4,2)
02.07.02 Vasoconstrictor sympathomimetics (5,0)
02.07.03 Cardiopulmonary resuscitation (1,0)
02.08 Anticoagulants (0,0)
02.08.01 Parenteral anticoagulants (1,0)
Heparin (1,0)
Low molecular weight heparins (1,3)
Heparinoids (1,0)
Hirudins (1,1)
Heparin flushes (2,2)
Epoprostenol (1,0)
Fondaparinux (1,0)
02.08.02 Oral anticoagulants (9,1)
VTE treatment (0,0)
VTE prophylaxis in hip/knee surgery (0,0)
Antidotes (0,0)
02.08.03 Protamine sulphate (3,0)
02.09 Antiplatelet drugs (7,6)
02.10 Stable angina, acute coronary syndromes, and fibrinolysis (0,0)
02.10.01 Management of stable angina and acute coronary syndromes (0,0)
02.10.02 Fibrinolytic drugs (4,1)
02.11 Antifibrinolytic drugs and haemostatics (3,7)
Blood-related products (1,10)
02.12 Lipid-regulating drugs (2,2)
Bile acid sequestrants (1,2)
Ezetimibe (1,0)
Fibrates (2,3)
Statins (4,3)
02.13 Local sclerosants (1,1)
netFormulary